vs
碧迪（BDX）与登士柏西诺德（XRAY）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是登士柏西诺德的5.5倍（$5.3B vs $961.0M）。碧迪净利率更高（7.3% vs -15.2%，领先22.5%）。登士柏西诺德同比增速更快（6.2% vs -0.4%）。碧迪自由现金流更多（$549.0M vs $60.0M）。过去两年碧迪的营收复合增速更高（2.0% vs 0.4%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
登士柏西诺德是美国牙科设备及耗材制造商，业务覆盖全球120多个国家，在21个国家设有生产工厂。该公司前身为1993年Gendex公司以5.9亿美元收购登士柏国际后整合组建的企业，是全球牙科领域的重要供应商。
BDX vs XRAY — 直观对比
营收规模更大
BDX
是对方的5.5倍
$961.0M
营收增速更快
XRAY
高出6.6%
-0.4%
净利率更高
BDX
高出22.5%
-15.2%
自由现金流更多
BDX
多$489.0M
$60.0M
两年增速更快
BDX
近两年复合增速
0.4%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $961.0M |
| 净利润 | $382.0M | $-146.0M |
| 毛利率 | 45.9% | 46.1% |
| 营业利润率 | 10.5% | -14.5% |
| 净利率 | 7.3% | -15.2% |
| 营收同比 | -0.4% | 6.2% |
| 净利润同比 | 24.0% | 66.0% |
| 每股收益（稀释后） | $1.34 | $-0.74 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXXRAY
| Q4 25 | $5.3B | $961.0M | ||
| Q3 25 | $5.9B | $904.0M | ||
| Q2 25 | $5.5B | $936.0M | ||
| Q1 25 | $5.3B | $879.0M | ||
| Q4 24 | $5.2B | $905.0M | ||
| Q3 24 | $5.4B | $951.0M | ||
| Q2 24 | $5.0B | $984.0M | ||
| Q1 24 | $5.0B | $953.0M |
净利润BDXXRAY
| Q4 25 | $382.0M | $-146.0M | ||
| Q3 25 | $493.0M | $-427.0M | ||
| Q2 25 | $574.0M | $-45.0M | ||
| Q1 25 | $308.0M | $20.0M | ||
| Q4 24 | $303.0M | $-430.0M | ||
| Q3 24 | $400.0M | $-494.0M | ||
| Q2 24 | $487.0M | $-4.0M | ||
| Q1 24 | $537.0M | $18.0M |
毛利率BDXXRAY
| Q4 25 | 45.9% | 46.1% | ||
| Q3 25 | 47.5% | 48.8% | ||
| Q2 25 | 47.8% | 52.4% | ||
| Q1 25 | 42.8% | 53.0% | ||
| Q4 24 | 43.2% | 49.3% | ||
| Q3 24 | 45.7% | 52.1% | ||
| Q2 24 | 46.2% | 51.9% | ||
| Q1 24 | 45.7% | 53.1% |
营业利润率BDXXRAY
| Q4 25 | 10.5% | -14.5% | ||
| Q3 25 | 11.8% | -24.1% | ||
| Q2 25 | 16.0% | -13.7% | ||
| Q1 25 | 10.4% | 7.2% | ||
| Q4 24 | 8.8% | -56.2% | ||
| Q3 24 | 11.4% | -48.6% | ||
| Q2 24 | 12.1% | 5.1% | ||
| Q1 24 | 14.5% | 4.4% |
净利率BDXXRAY
| Q4 25 | 7.3% | -15.2% | ||
| Q3 25 | 8.4% | -47.2% | ||
| Q2 25 | 10.4% | -4.8% | ||
| Q1 25 | 5.8% | 2.3% | ||
| Q4 24 | 5.9% | -47.5% | ||
| Q3 24 | 7.4% | -51.9% | ||
| Q2 24 | 9.8% | -0.4% | ||
| Q1 24 | 10.6% | 1.9% |
每股收益（稀释后）BDXXRAY
| Q4 25 | $1.34 | $-0.74 | ||
| Q3 25 | $1.71 | $-2.14 | ||
| Q2 25 | $2.00 | $-0.22 | ||
| Q1 25 | $1.07 | $0.10 | ||
| Q4 24 | $1.04 | $-2.09 | ||
| Q3 24 | $1.37 | $-2.46 | ||
| Q2 24 | $1.68 | $-0.02 | ||
| Q1 24 | $1.85 | $0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $326.0M |
| 总债务越低越好 | — | $2.3B |
| 股东权益账面价值 | $25.3B | $1.3B |
| 总资产 | $54.8B | $5.4B |
| 负债/权益比越低杠杆越低 | — | 1.70× |
8季度趋势，按日历期对齐
现金及短期投资BDXXRAY
| Q4 25 | $740.0M | $326.0M | ||
| Q3 25 | $641.0M | $363.0M | ||
| Q2 25 | $735.0M | $359.0M | ||
| Q1 25 | $667.0M | $398.0M | ||
| Q4 24 | $711.0M | $272.0M | ||
| Q3 24 | $1.7B | $296.0M | ||
| Q2 24 | $4.5B | $279.0M | ||
| Q1 24 | $2.3B | $291.0M |
总债务BDXXRAY
| Q4 25 | — | $2.3B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDXXRAY
| Q4 25 | $25.3B | $1.3B | ||
| Q3 25 | $25.4B | $1.5B | ||
| Q2 25 | $25.5B | $2.0B | ||
| Q1 25 | $25.2B | $2.0B | ||
| Q4 24 | $25.2B | $1.9B | ||
| Q3 24 | $25.9B | $2.5B | ||
| Q2 24 | $25.9B | $3.1B | ||
| Q1 24 | $25.6B | $3.3B |
总资产BDXXRAY
| Q4 25 | $54.8B | $5.4B | ||
| Q3 25 | $55.3B | $5.7B | ||
| Q2 25 | $54.9B | $6.1B | ||
| Q1 25 | $54.5B | $6.0B | ||
| Q4 24 | $54.7B | $5.8B | ||
| Q3 24 | $57.3B | $6.6B | ||
| Q2 24 | $55.6B | $6.9B | ||
| Q1 24 | $54.2B | $7.1B |
负债/权益比BDXXRAY
| Q4 25 | — | 1.70× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $101.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $60.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 6.2% |
| 资本支出强度资本支出/营收 | 2.1% | 4.3% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | $104.0M |
8季度趋势，按日历期对齐
经营现金流BDXXRAY
| Q4 25 | $657.0M | $101.0M | ||
| Q3 25 | $1.4B | $79.0M | ||
| Q2 25 | $1.2B | $48.0M | ||
| Q1 25 | $164.0M | $7.0M | ||
| Q4 24 | $693.0M | $87.0M | ||
| Q3 24 | $1.2B | $141.0M | ||
| Q2 24 | $1.3B | $208.0M | ||
| Q1 24 | $514.0M | $25.0M |
自由现金流BDXXRAY
| Q4 25 | $549.0M | $60.0M | ||
| Q3 25 | $1.0B | $40.0M | ||
| Q2 25 | $1.0B | $16.0M | ||
| Q1 25 | $35.0M | $-12.0M | ||
| Q4 24 | $588.0M | $36.0M | ||
| Q3 24 | $882.0M | $98.0M | ||
| Q2 24 | $1.1B | $156.0M | ||
| Q1 24 | $380.0M | $-9.0M |
自由现金流率BDXXRAY
| Q4 25 | 10.5% | 6.2% | ||
| Q3 25 | 17.0% | 4.4% | ||
| Q2 25 | 19.0% | 1.7% | ||
| Q1 25 | 0.7% | -1.4% | ||
| Q4 24 | 11.4% | 4.0% | ||
| Q3 24 | 16.2% | 10.3% | ||
| Q2 24 | 22.4% | 15.9% | ||
| Q1 24 | 7.5% | -0.9% |
资本支出强度BDXXRAY
| Q4 25 | 2.1% | 4.3% | ||
| Q3 25 | 6.0% | 4.3% | ||
| Q2 25 | 3.2% | 3.4% | ||
| Q1 25 | 2.4% | 2.2% | ||
| Q4 24 | 2.0% | 5.6% | ||
| Q3 24 | 5.4% | 4.5% | ||
| Q2 24 | 3.6% | 5.3% | ||
| Q1 24 | 2.7% | 3.6% |
现金转化率BDXXRAY
| Q4 25 | 1.72× | — | ||
| Q3 25 | 2.75× | — | ||
| Q2 25 | 2.12× | — | ||
| Q1 25 | 0.53× | 0.35× | ||
| Q4 24 | 2.29× | — | ||
| Q3 24 | 2.94× | — | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | 1.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
XRAY
| Essential Dental Solutions | $372.0M | 39% |
| Equipment And Instruments | $160.0M | 17% |
| Implants And Prosthetics | $150.0M | 16% |
| CADCAM | $139.0M | 14% |
| Wellspect Healthcare | $88.0M | 9% |
| Orthodontics | $52.0M | 5% |
